Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

3 results about "Heartburn" patented technology

A sensation of painful burning in the upper chest.

Application of Wangshi Bachi Pills in the Treatment of Helicobacter Pylori Infection

ActiveCN117503865BMicrobiologyHelicobacter Infections
The application discloses application of Wangshi Baochi pills in treatment of Helicobacter pylori infection and belongs to the technical field of medicines. The application provides the application of the Wangshi Baochi pills in treatment of Helicobacter pylori infection, which can achieve ideal treatment effects under the condition that the dosage of antibiotics is halved and bismuth agents are not used, and can better relieve the clinical symptoms of pain, belching, acid regurgitation and heartburn.
Owner:JINGHUA PHARMA GRP

Pharmaceutical Formulations and Methods for the Treatment of Gastrointestinal Disorders

PendingUS20260125373A1Organic active ingredientsDigestive systemDisease irritable bowelDisease
Provided herein is a bulk composition comprising the trihydrate form of (3S, 4R, 3′R)-6-[4-(4-amino-5-chloro-2-methoxy-benzoylamino)-3-methoxy-piperidin-1-yl]-hexanoic acid 1-azabicyclo[2.2.2]oct-3′-yl ester di-hydrochloride salt. Provided are also pharmaceutical compositions and dosage forms comprising the trihydrate form, and methods and uses for treating a gastrointestinal disorder in a subject with the trihydrate form. In some embodiments, the gastrointestinal disorder is gastroesophageal reflux disease (GERD), dyspepsia (such as functional dyspepsia or functional motility disorder), gastroparesis, paralytic ileus, post-operative ileus, emesis, nausea, heartburn, intestinal pseudo-obstruction, irritable bowel syndrome (IBS), constipation, enteral feeding intolerance (EFI), or esophagitis. In some embodiments, the gastrointestinal disorder is post-operative ileus, chronic grass sickness, constipation, megacolon, gastritis, gastrointestinal stasis, or abomasal emptying defect.
Owner:RENEXXION LLC

Unit oral dose compositions composed of ibuprofen or a pharmaceutically acceptable salt thereof and famotidine or a pharmaceutically acceptable salt thereof for the treatment of acute pain and the reduction of the severity and / or risk of heartburn and / or upset stomach

Described herein are unit oral dose compositions that reduce the severity of heartburn and / or upset stomach or the risk of the occurrence of heartburn and / or upset stomach in a human in need of taking ibuprofen or the pharmaceutically acceptable salt thereof for the treatment of acute pain wherein the human is not experiencing heartburn and / or upset stomach prior to the oral administration of the unit oral dose composition comprising orally administering to the human of a unit oral dose composition comprising (i) ibuprofen or the pharmaceutically acceptable salt thereof, wherein the amount of ibuprofen or the conjugate base of ibuprofen of the pharmaceutically acceptable salt of ibuprofen is a dosage from about 50 mg to about 400 mg per unit oral dose composition and (ii) famotidine or the pharmaceutically acceptable salt thereof, wherein famotidine or the conjugate acid of famotidine of the pharmaceutically acceptable salt of famotidine is at a dosage from about 3 mg to about 20 mg per unit oral dose composition, wherein the dissolution rate of famotidine or the conjugate acid of famotidine of the pharmaceutically acceptable salt of famotidine in the unit oral dose composition in said human at a specified time within 45 minutes of administration of said unit oral dose composition to said human is greater than the dissolution rate of ibuprofen or the conjugate base of ibuprofen of the pharmaceutically acceptable salt of ibuprofen in the unit oral dose composition in said human at the same specified time.
Owner:SCHABAR RESEARCH ASSOCIATES LLC